The chief executive-in-waiting of Germany's Bayer, Marijn Dekkers, has said the company is still looking for acquisitions and could envision another large deal in the same league as its $23 billion purchase of Schering in 2006.
Dekkers, who takes over the CEO role from Werner Wenning on October 1, made the comments at an industry dinner on Monday, according to a report in Germany business daily Handelsblatt.
He said the company will try to bolster its existing business units rather than diversify into new areas, and will focus instead on expanding its presence in emerging markets. Bayer has already shown that growth by acquisition can be an attractive strategy under Wenning's leadership, added Dekkers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze